An Ophthalmic Safety Study in Patients With Breast Cancer

Description

To assess ophthalmic health in parallel cohorts of patients with breast cancer

Conditions

Ophthalmic Safety in Patients With Breast Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

To assess ophthalmic health in parallel cohorts of patients with breast cancer

A Multicentre Study Assessing Ophthalmic Safety in Patients With Breast Cancer

An Ophthalmic Safety Study in Patients With Breast Cancer

Condition
Ophthalmic Safety in Patients With Breast Cancer
Intervention / Treatment

-

Contacts and Locations

La Jolla

Research Site, La Jolla, California, United States, 92093

Palo Alto

Research Site, Palo Alto, California, United States, 94304

San Diego

Research Site, San Diego, California, United States, 92123

Iowa City

Research Site, Iowa City, Iowa, United States, 52242

New York

Research Site, New York, New York, United States, 10029

Winston-Salem

Research Site, Winston-Salem, North Carolina, United States, 27104

Cleveland

Research Site, Cleveland, Ohio, United States, 44195

Clairton

Research Site, Clairton, Pennsylvania, United States, 15025

Pittsburgh

Research Site, Pittsburgh, Pennsylvania, United States, 15219

Sioux Falls

Research Site, Sioux Falls, South Dakota, United States, 57105

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Signed informed consent in the qualifying study.
  • 2. Signed informed consent in the ophthalmic study prior to any ophthalmic study specific assessments and procedures.
  • 3. Completed the baseline ophthalmic examination for this study before the first dose in the qualifying study.
  • 4. Meets all the eligibility criteria in the qualifying study
  • 1. Patients not randomized and not receiving study assigned treatment in a qualifying study.
  • 2. Patients with contraindications to any ophthalmic procedure required by the study or sensitivity/allergy to pupil dilating agents.
  • 3. Judgement by the investigator that the patient should not participate in the ophthalmic study if the patient is unlikely to comply with study procedures, restrictions, and requirements

Ages Eligible for Study

18 Years to 130 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

AstraZeneca,

Study Record Dates

2027-07-06